# Does Missouri Medicaid Cover Zepbound and Wegovy? MO HealthNet's GLP-1 Rules

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-11-06

Canonical page: https://glpwatchdog.org/research/missouri-medicaid-glp1-coverage

> Missouri Medicaid pays for weight-loss GLP-1s, but only its preferred ones: Zepbound and the Foundayo pill. Wegovy is limited to heart risk and MASH, without diabetes, in four-week steps. The routes, ages, Form 2575-053, diabetes drugs and appeals.

## Key points

- Zepbound, the Zepbound KwikPen and Foundayo are MO HealthNet's preferred weight-loss drugs on the November 2026 list.
- Adults qualify at BMI 30, or at 27 when a listed condition is present, and other routes cover MASH, antipsychotic use and teenagers.
- Wegovy is never covered for weight loss; it needs proof of no diabetes plus heart disease from age 45, or MASH.
- Wegovy approvals come four weeks at a time until the dose reaches 1.7 mg, while the default approval elsewhere is 90 days.
- Pharmacy is carved out of managed care, so every Missouri Medicaid plan follows the same GLP-1 criteria.

Yes for Zepbound, no for Wegovy. As of November 2026, MO HealthNet, Missouri’s Medicaid program, covers Zepbound and the Foundayo pill for weight loss with prior authorization, for adults whose BMI reaches 30, or 27 when a related health problem is present.[1][3] Wegovy is not covered for weight loss at all; it is approved only to lower heart risk or treat the liver disease MASH, in people with no diabetes.[2]

> **About this article.** This page reads MO HealthNet’s prior authorization criteria for GLP-1s used for obesity (revised April 23, 2026), its GLP-1 request form 2575-053 (April 2026) and its preferred drug list effective November 1, 2026, as they stood on November 6, 2026. Missouri pays pharmacy claims through one statewide program for every member, so these rules apply whichever health plan you are in. To compare states, use the [state Medicaid GLP-1 checker](https://glpwatchdog.org/tools/state-medicaid-glp1-checker).

## Does Missouri Medicaid cover Zepbound for weight loss?

Yes. MO HealthNet used to leave weight-loss drugs out, an option states have under federal law, and its criteria document says so plainly before explaining why it began covering selected ones.[1][5] Those criteria were first put in place on January 9, 2025.[1] On the drug list effective November 1, 2026, the obesity class has three preferred products, Foundayo, Zepbound and the Zepbound KwikPen, and one non-preferred product, Wegovy.[3] Any weight-loss drug not named in the policy stays excluded.[1] For how other programs handle this drug, see our guide to [Medicaid coverage of Zepbound by state](https://glpwatchdog.org/research/does-medicaid-cover-zepbound).

## Who qualifies for Zepbound or Foundayo through MO HealthNet?

The request must meet one of these routes, documented in the record:[1][2]

*MO HealthNet routes for Zepbound and Foundayo, from the obesity criteria revised April 23, 2026 and Form 2575-053*

| Route | What qualifies |
| --- | --- |
| Adult, BMI 30 or more | Baseline BMI of 30 or more |
| Adult, BMI 27 or more with a condition | High blood pressure, high cholesterol, sleep apnea, prediabetes (A1C 5.7–6.4% or a matching glucose test), a past heart attack or stroke, symptomatic peripheral artery disease, or type 2 diabetes |
| Adult with MASH | F2 or F3 liver fibrosis confirmed by a recent biopsy or noninvasive testing |
| Antipsychotic treatment | Current antipsychotic therapy, documented |
| Ages 12 to 17 | A starting BMI in the top 5% for their age and sex (Zepbound only; Foundayo starts at 18) |
| Already on a preferred drug | Documented adherence to current preferred-drug therapy |

Two features stand out. Current antipsychotic treatment is a route of its own, and the list of qualifying conditions includes type 2 diabetes and sleep apnea, so people with those conditions use the same weight route rather than a separate one.[1] The age line also stands out: the criteria accept Zepbound claims from age 12, while the drug’s FDA label covers adults only.[1][7] Foundayo is limited to adults, which matches its label.[1][9] Our explainer on the BMI lines for Wegovy and Zepbound sets the state’s numbers against the labels.

People who started Zepbound before MO HealthNet covered it must send the BMI at the start of treatment as well as today, how they paid, and the three most recent fill dates.[2] The default approval period in the criteria is 90 days, and a second GLP-1 at the same time is denied.[1] Our page on [Foundayo, the daily orforglipron pill](https://glpwatchdog.org/research/foundayo-orforglipron-oral-glp1) covers the newer preferred option.

## When will MO HealthNet pay for Wegovy?

Only for two uses, and never for weight loss: the form says Wegovy for reducing or keeping off excess weight “is not covered by MO HealthNet.”[2] Both remaining routes require proof that the person does not have diabetes: an A1C under 6.5 from the past three months and no diabetes diagnosis or diabetes medicine in the past two years.[1]

*MO HealthNet Wegovy routes, from the obesity criteria revised April 23, 2026*

| Use | Requirements |
| --- | --- |
| Lowering heart attack and stroke risk | Age 45 or older; baseline BMI of 27 or more; a prior heart attack, a prior stroke, or peripheral artery disease with symptoms; current heart medicines documented; no diabetes |
| MASH with F2 or F3 fibrosis | Age 18 or older; biopsy or noninvasive confirmation; current liver function tests; a gastroenterologist, liver specialist or other specialist involved; no diabetes |

The approvals come in short steps. The first lasts four weeks, and each dose during titration needs its own four-week approval until the patient reaches at least 1.7 mg; one extra four weeks at a dose may be approved once, with documented side effects the patient could not tolerate.[1][2] A patient who cannot reach 1.7 mg within six months is denied.[1] Wegovy’s label allows the heart use in any adult, so the age-45 line is the state’s own.[8] Our page on [GLP-1 treatment for MASH](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash) explains the liver evidence.

## Does MO HealthNet cover Ozempic and Mounjaro for diabetes?

Yes, with a diabetes diagnosis. Mounjaro, the Ozempic injection, Trulicity and Victoza are preferred on the November 2026 list; the non-preferred ones include generic liraglutide, exenatide, Rybelsus and the Ozempic tablet.[3] A non-preferred diabetes GLP-1 needs trials of three preferred drugs for three months each, with notes on why each was stopped, and the form asks about a metformin trial.[2] The April form lists Byetta as preferred while the November list shows it as non-preferred, so check the current list for that drug.[2][3]

## How do you file, and does your health plan matter?

Your health plan does not change the drug rules. Missouri carves pharmacy out of managed care and pays it through fee-for-service, so members of Healthy Blue, Home State Health, UnitedHealthcare and Show Me Healthy Kids all use the state’s criteria.[4] The prescriber sends Form 2575-053 by fax to (573) 636-6470, and drug-specific questions go to (800) 392-8030.[2] The form warns that a request missing information will not be processed.[2]

## How do you appeal a MO HealthNet denial?

Check whether the denial is about the drug or the paperwork. Asking for Wegovy for weight loss cannot succeed, because the program excludes it, but the same patient may qualify for Zepbound.[2][1] A missing A1C, BMI date or fill history is a records problem that can be fixed by refiling.[2]

Because pharmacy is handled by the state program, a formal appeal is a request for a state fair hearing. Federal rules cap the time a state may allow for that request at 90 days from the date the notice is mailed, so use the date printed on your notice.[6] Our walkthrough of [prior authorization and appeals](https://glpwatchdog.org/research/glp1-prior-authorization-and-appeals) covers what to send, and the [Missouri state page](https://glpwatchdog.org/states/missouri) keeps the basics together.

## What if MO HealthNet will not pay?

Cash is the fallback, and Lilly’s savings card excludes Medicaid members.[10] Novo Nordisk’s self-pay price for most Wegovy pen doses is $349 a month, and Lilly’s Zepbound KwikPen costs $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled within 45 days.[10][11] Check each program’s rules for government coverage first. Our list of the [cheapest GLP-1 options without insurance](https://glpwatchdog.org/research/cheapest-glp1-without-insurance) compares them.

## Frequently asked questions

### Does Missouri Medicaid cover Wegovy for weight loss?

No. MO HealthNet's form says Wegovy for weight loss is not covered. As of November 2026 it approves Wegovy only to lower heart risk at age 45 or older for people who have had a heart attack or stroke or have peripheral artery disease with symptoms, or to treat MASH, and only for people without diabetes.

### Does Missouri Medicaid cover Zepbound?

Yes. Zepbound is a preferred weight-loss drug for MO HealthNet. Adults qualify from a BMI of 30, or from 27 when they also have a condition such as high blood pressure, sleep apnea or prediabetes, and other routes cover MASH, antipsychotic treatment and teenagers with a high BMI percentile.

### Does MO HealthNet cover Foundayo?

Yes. Foundayo is a preferred weight-loss drug for adults 18 and older on the list effective November 1, 2026, under the same criteria as Zepbound.

### How long does a MO HealthNet GLP-1 approval last?

The obesity criteria set a default approval period of 90 days. Wegovy is different: approvals last four weeks at a time until the dose reaches at least 1.7 mg.

### Does my Missouri Medicaid health plan have different GLP-1 rules?

No. Pharmacy is carved out of managed care in Missouri and paid through the state's fee-for-service program, so the same criteria apply in every health plan.

## References

1. MO HealthNet Division and Conduent SmartPA Criteria: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Indicated for Obesity PDL Edit (revised April 23, 2026). dss.mo.gov. 2026. https://dss.mo.gov/sites/mydss/files/media/file/2026/05/GLP-1%20for%20Obesity%20PDL%204-23-26_1.docx
2. MO HealthNet Division Form 2575-053: GLP-1 Receptor Agonists for All Indications Prior Authorization (April 2026). dss.mo.gov. 2026. https://dss.mo.gov/sites/mydss/files/media/pdf/2026/09/Remediated_2575-053-GLP-1-Receptor-Agonists-PA-Form.pdf
3. MO HealthNet Division Preferred Drug List static document, effective November 1, 2026. dss.mo.gov. 2026. https://dss.mo.gov/sites/mydss/files/media/file/2026/10/PDL%20Static%20Document%2011-01-2026.xlsx
4. Missouri Department of Social Services, MO HealthNet Division Provider Manuals: managed care providers and carved-out services. mydss.mo.gov. 2026. https://mydss.mo.gov/mhd/provider-manuals
5. United States Code 42 U.S.C. §1396r-8: Payment for covered outpatient drugs (Social Security Act §1927). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8
6. Centers for Medicare & Medicaid Services 42 CFR 431.221: Request for hearing. eCFR. 2026. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-C/part-431/subpart-E/section-431.221
7. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
8. Novo Nordisk WEGOVY (semaglutide) injection and tablets: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
9. Eli Lilly and Company FOUNDAYO (orforglipron) tablets: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
10. Eli Lilly and Company Zepbound savings and self-pay options, with card terms. zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings
11. Novo Nordisk Wegovy savings offer. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html

---

Cite as: GLP Watchdog, Nora Bissett, "Does Missouri Medicaid Cover Zepbound and Wegovy? MO HealthNet's GLP-1 Rules", published 2026-11-06. https://glpwatchdog.org/research/missouri-medicaid-glp1-coverage

Canonical HTML page: https://glpwatchdog.org/research/missouri-medicaid-glp1-coverage

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.